XTLB Quote, Financials, Valuation and Earnings

Can Fite Biofarma has a net margin of -- compared to XTL Biopharmaceuticals's net margin of --. XTL Biopharmaceuticals's return on equity of -- beat Can Fite Biofarma's return on equity of --.

XTL Biopharmaceuticals has a consensus price target of --, signalling upside risk potential of 1983.33%. On the other hand Can Fite Biofarma has an analysts' consensus of -- which suggests that it could grow by 845.95%. Given that XTL Biopharmaceuticals has higher upside potential than Can Fite Biofarma, analysts believe XTL Biopharmaceuticals is more attractive than Can Fite Biofarma.

XTL Biopharmaceuticals has a beta of 1.156, which suggesting that the stock is 15.571% more volatile than S&P 500. In comparison Can Fite Biofarma has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.764%.

XTL Biopharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can Fite Biofarma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals pays -- of its earnings as a dividend. Can Fite Biofarma pays out -- of its earnings as a dividend.

XTL Biopharmaceuticals quarterly revenues are --, which are smaller than Can Fite Biofarma quarterly revenues of --. XTL Biopharmaceuticals's net income of $485K is higher than Can Fite Biofarma's net income of --. Notably, XTL Biopharmaceuticals's price-to-earnings ratio is -- while Can Fite Biofarma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals is -- versus 13.42x for Can Fite Biofarma. Usually stocks with elevated PS ratios are considered overvalued.

Compugen has a net margin of -- compared to XTL Biopharmaceuticals's net margin of 7.45%. XTL Biopharmaceuticals's return on equity of -- beat Compugen's return on equity of 2.69%.

XTL Biopharmaceuticals has a consensus price target of --, signalling upside risk potential of 1983.33%. On the other hand Compugen has an analysts' consensus of -- which suggests that it could grow by 159.74%. Given that XTL Biopharmaceuticals has higher upside potential than Compugen, analysts believe XTL Biopharmaceuticals is more attractive than Compugen.

XTL Biopharmaceuticals has a beta of 1.156, which suggesting that the stock is 15.571% more volatile than S&P 500. In comparison Compugen has a beta of 2.588, suggesting its more volatile than the S&P 500 by 158.818%.

XTL Biopharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals pays -- of its earnings as a dividend. Compugen pays out -- of its earnings as a dividend.

XTL Biopharmaceuticals quarterly revenues are --, which are smaller than Compugen quarterly revenues of $17.1M. XTL Biopharmaceuticals's net income of $485K is lower than Compugen's net income of $1.3M. Notably, XTL Biopharmaceuticals's price-to-earnings ratio is -- while Compugen's PE ratio is 51.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals is -- versus 2.30x for Compugen. Usually stocks with elevated PS ratios are considered overvalued.

BiomX has a net margin of -- compared to XTL Biopharmaceuticals's net margin of --. XTL Biopharmaceuticals's return on equity of -- beat BiomX's return on equity of --.

XTL Biopharmaceuticals has a consensus price target of --, signalling upside risk potential of 1983.33%. On the other hand BiomX has an analysts' consensus of -- which suggests that it could grow by 1029.03%. Given that XTL Biopharmaceuticals has higher upside potential than BiomX, analysts believe XTL Biopharmaceuticals is more attractive than BiomX.

XTL Biopharmaceuticals has a beta of 1.156, which suggesting that the stock is 15.571% more volatile than S&P 500. In comparison BiomX has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.404%.

XTL Biopharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals pays -- of its earnings as a dividend. BiomX pays out -- of its earnings as a dividend.

XTL Biopharmaceuticals quarterly revenues are --, which are smaller than BiomX quarterly revenues of --. XTL Biopharmaceuticals's net income of $485K is lower than BiomX's net income of $9.6M. Notably, XTL Biopharmaceuticals's price-to-earnings ratio is -- while BiomX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals is -- versus -- for BiomX. Usually stocks with elevated PS ratios are considered overvalued.

Pluri has a net margin of -- compared to XTL Biopharmaceuticals's net margin of -1804.3%. XTL Biopharmaceuticals's return on equity of -- beat Pluri's return on equity of -438.78%.

XTL Biopharmaceuticals has a consensus price target of --, signalling upside risk potential of 1983.33%. On the other hand Pluri has an analysts' consensus of -- which suggests that it could grow by 563.9%. Given that XTL Biopharmaceuticals has higher upside potential than Pluri, analysts believe XTL Biopharmaceuticals is more attractive than Pluri.

XTL Biopharmaceuticals has a beta of 1.156, which suggesting that the stock is 15.571% more volatile than S&P 500. In comparison Pluri has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.245%.

XTL Biopharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals pays -- of its earnings as a dividend. Pluri pays out -- of its earnings as a dividend.

XTL Biopharmaceuticals quarterly revenues are --, which are smaller than Pluri quarterly revenues of $326K. XTL Biopharmaceuticals's net income of $485K is higher than Pluri's net income of -$5.9M. Notably, XTL Biopharmaceuticals's price-to-earnings ratio is -- while Pluri's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals is -- versus 42.82x for Pluri. Usually stocks with elevated PS ratios are considered overvalued.